Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page
- CheckyesterdayChange DetectedThe Study Details page for NCT03412773 appears the same in both screenshots, with no changes to the main study information.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded detailed trial results and substudy information for the tislelizumab vs sorafenib study (RATIONALE-301), including endpoints, locations, and Japanese safety run-in; removed reference to the 2024-01-10 results submission page in favor of the updated results-centric content.SummaryDifference100%

- Check30 days agoChange DetectedUpdate includes a government operations notice and new version tag v3.2.0, replacing v3.1.0.SummaryDifference2%

- Check37 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page revision is updated from v3.0.1 to v3.0.2. The 'Back to Top' navigation element has been removed.SummaryDifference0.1%

- Check58 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content.SummaryDifference0.1%

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.